about
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic lociSolution structure of midkine, a new heparin-binding growth factorStructural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and speciescDNA cloning, genomic organization and chromosomal localization of human heparan glucosaminyl N-deacetylase/N-sulphotransferase-2Expression of heparan sulphate L-iduronyl 2-O-sulphotransferase in human kidney 293 cells results in increased D-glucuronyl 2-O-sulphationLatexin, a carboxypeptidase A inhibitor, is expressed in rat peritoneal mast cells and is associated with granular structures distinct from secretory granules and lysosomesEnhanced glycosylation and sulfation of secretory proteoglycans is coupled to the expression of a basic secretory proteinMarine Origin Polysaccharides in Drug Delivery Systems.A Turn-like Structure "KKPE" Segment Mediates the Specific Binding of Viral Protein A27 to Heparin and Heparan Sulfate on Cell SurfacesStructural Basis of Oligosaccharide Receptor Recognition by Human PapillomavirusDeleted in colorectal carcinoma (DCC) binds heparin via its fifth fibronectin type III domainNeurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surfaceReceptors for fibroblast growth factorsCombined strong anion-exchange HPLC and PAGE approach for the purification of heparan sulphate oligosaccharidesPreparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrierThe amino-terminal part of PRELP binds to heparin and heparan sulfateSynthesis and distribution of glycosaminoglycans in human leukemic B- and T-cells and monocytes studied using specific enzymic treatments and high-performance liquid chromatography.Effects of mitogens on synthesis and distribution of heparan and chondroitin sulphates by human leukemic B, T cells and monocytes studied by high-performance liquid chromatography and radiochemical detection.Analysis of glycosaminoglycan-derived disaccharides in biologic samples by capillary electrophoresis and protocol for sequencing glycosaminoglycans.Purification of a 75 kDa protein from the organelle matrix of human neutrophils and identification as N-acetylglucosamine-6-sulphatase.Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney.Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I.Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.Heparan sulfate domain organization and sulfation modulate FGF-induced cell signalingGlycosaminoglycan sulfation requirements for respiratory syncytial virus infection.Activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells.Bottom-up low molecular weight heparin analysis using liquid chromatography-Fourier transform mass spectrometry for extensive characterizationStructural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells.On the blood compatibility of end-point immobilized heparin.Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.Heparin-protein interactions.Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-ESelective Expansion of CD34+ Cells from Mouse Bone Marrow Cultured on LH/P MP-Coated Plates with Adequate CytokinesHeparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery systemHeparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells.Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey.Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonistsPeriodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung.Tissue compatibility of interfacial polyelectrolyte complexation fibrous scaffold: evaluation of blood compatibility and biocompatibility.
P2860
Q22001455-4EF528DA-E07D-4C0D-8825-C472425092DCQ24310244-AD6E87FA-4F94-4E78-8476-34BC95BB1503Q24530061-0F810F66-2854-40CC-A170-14F53823B3D5Q24530865-C438ED99-E3CA-4179-83B7-22360F94AFB0Q24531959-710E763A-6222-4935-84DF-FF71F205B622Q24531990-D61D743C-860B-46BF-95AE-F487FE99FB45Q24655244-D7E666AD-3392-431D-8954-CFB137E40CBFQ26767227-C3A3F4D5-40DD-4CBC-8A2E-23D0795503D4Q27490518-2CBC9630-1BA1-4B35-9749-2A6D783425C9Q27666101-31E6D493-4769-4615-BAF5-F9ECD9CF3F6CQ28252122-8EB55E50-D1C6-448C-98AF-022BC65ACECEQ28273686-9FD24C8A-5EB4-4CEE-B737-ABC8623DEB5AQ28285082-A78E4BF2-2A0A-45C8-8C57-9C53FA900AC4Q28348093-C9D0D278-8AFD-40E4-8772-DD40A10CC4D2Q28395304-0263641D-E683-41F2-86B1-D16C9C532233Q28573289-E7712630-B6E5-4896-8D54-D7691BA9472AQ30665086-01492868-E463-4568-9E38-D787D09419BDQ30781026-13FAADD2-3CF5-4049-B726-D1317045D1F4Q30816669-A5153DD4-8F71-4524-BA68-F891B1BEA019Q31135804-1822A104-5831-4A5C-B331-748B755924C2Q32064386-BBDEE4DD-91A4-4634-8C62-BA9986F59C07Q32068517-7AFAF410-B528-4485-A48F-62A6E5BE59E8Q33410310-7A7194CF-12FC-4153-A557-A53174E9048AQ33615579-CE8A856F-EE14-44C5-B072-402BE2CFFE7EQ33787265-9431C409-4A16-4B5B-AFFA-58576E2FAEA2Q33805045-6F7D9A9F-BF1E-45A5-883A-0FA4FFDFD25FQ33847730-3A774DB1-1104-4F8F-ABB2-0CE1B09F7CFCQ34071225-FA26D1C8-3FAB-4D0C-ABD9-FB41618B3218Q34192479-D4B83879-4FD2-468D-9C76-86A2FA3ECE4DQ34448852-DC56A7A6-2B47-4A59-950F-8DEC1580CEE2Q35030190-E547871F-61AF-4647-A71C-03570C859889Q35489874-60FCC676-8D61-4303-9DFC-AA936D8A2312Q35674413-C9322193-6960-42EC-AE16-16ECBF7DB637Q36025124-3318A61B-0EDB-44EC-B7D6-F5F40B8F6C39Q36352469-C015276C-67A7-40A6-8D80-05C1D4173473Q36367585-E270610A-AD3B-4FD8-BF3B-5CECFB815D41Q36489766-CB42374D-AF1D-4E18-9286-C9987EA4F115Q36526260-15501503-B8EF-4AE2-8A2E-B8E931907DC1Q36644517-0ED0801B-61A3-485A-82A3-ED6A75A9E50DQ36737354-48B0E6EF-9071-44E6-BFEC-ED44467D5A20
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
More to "heparin" than anticoagulation.
@en
type
label
More to "heparin" than anticoagulation.
@en
prefLabel
More to "heparin" than anticoagulation.
@en
P1433
P1476
More to "heparin" than anticoagulation.
@en
P2093
Spillmann D
P356
10.1016/0049-3848(94)90136-8
P577
1994-07-01T00:00:00Z